7BWJ

crystal structure of SARS-CoV-2 antibody with RBD

Summary for 7BWJ

• Entry DOI: 10.2210/pdb7bwj/pdb
• Descriptor: Spike protein S1, antibody light chain, antibody heavy chain, ... (4 entities in total)
• Functional Keywords: spike, receptor binding domain, antibody, viral protein
• Biological source: Severe acute respiratory syndrome coronavirus 2 (2019-nCoV); More
• Total number of polymer chains: 3
• Total formula weight: 71631.00

Authors

Wang, X.,Ge, J. (deposition date: 2020-04-14, release date: 2020-06-03, Last modification date: 2024-10-23)

Primary citation

Ju, B.,Zhang, Q.,Ge, J.,Wang, R.,Sun, J.,Ge, X.,Yu, J.,Shan, S.,Zhou, B.,Song, S.,Tang, X.,Yu, J.,Lan, J.,Yuan, J.,Wang, H.,Zhao, J.,Zhang, S.,Wang, Y.,Shi, X.,Liu, L.,Zhao, J.,Wang, X.,Zhang, Z.,Zhang, L.
Human neutralizing antibodies elicited by SARS-CoV-2 infection.
Nature, 584:115-119, 2020

PubMed Abstract: The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) presents a global health emergency that is in urgent need of intervention. The entry of SARS-CoV-2 into its target cells depends on binding between the receptor-binding domain (RBD) of the viral spike protein and its cellular receptor, angiotensin-converting enzyme 2 (ACE2). Here we report the isolation and characterization of 206 RBD-specific monoclonal antibodies derived from single B cells from 8 individuals infected with SARS-CoV-2. We identified antibodies that potently neutralize SARS-CoV-2; this activity correlates with competition with ACE2 for binding to RBD. Unexpectedly, the anti-SARS-CoV-2 antibodies and the infected plasma did not cross-react with the RBDs of SARS-CoV or Middle East respiratory syndrome-related coronavirus (MERS-CoV), although there was substantial plasma cross-reactivity to their trimeric spike proteins. Analysis of the crystal structure of RBD-bound antibody revealed that steric hindrance inhibits viral engagement with ACE2, thereby blocking viral entry. These findings suggest that anti-RBD antibodies are largely viral-species-specific inhibitors. The antibodies identified here may be candidates for development of clinical interventions against SARS-CoV-2.

PubMed: 32454513
DOI: 10.1038/s41586-020-2380-z

Experimental method

X-RAY DIFFRACTION (2.85 Å)